Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
77 hedge funds and large institutions have $80.2M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 12 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 80 → 77 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
34% less capital invested
Capital invested by funds: $122M → $80.2M (-$41.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$635K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$433K |
| 3 |
BlackRock
New York
|
+$401K |
| 4 |
JP Morgan Chase
New York
|
+$261K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$258K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.43M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.26M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.03M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$726K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$472K |
JNCE Hedge Fund Activity: Q3 2019 in Review
77 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2019, worth a combined $80.2M — down 34% from $122M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of JNCE and 9 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 29 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $635K. The largest seller was AQR Capital Management, exiting entirely with an estimated $1.43M sold.
- 77 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2019, down from 80 in Q2 2019.
- Funds reported $80.2M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2019, down 34% quarter-over-quarter.
- 9 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2019 and 12 closed out, a net change of -3 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2019 was Millennium Management, an estimated $635K added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2019 was AQR Capital Management, an estimated $1.43M sold.
Based on aggregated 13F filings for Q3 2019.